Amrane Karim, Le Goupil Delphine, Quere Gilles, Delcroix Olivier, Gouva Sylvie, Schick Ulrike, Salaun Pierre-Yves, Abgral Ronan, Alavi Zarrin, Keromnes Nathalie, Querellou Solène
Oncology Department.
Nuclear Medicine Department.
Medicine (Baltimore). 2019 Jul;98(29):e16417. doi: 10.1097/MD.0000000000016417.
We aimed to assess serial F-FDG PET/CT imaging according to morphological (RECIST1.1, iRECIST) and functional (PERCIST, PECRIT) criteria to predict clinical response to therapy in patients with advanced melanoma receiving immune checkpoint blocking agents.Retrospective data collection and analysis was done for 37 patients with unresectable metastatic cutaneous melanoma eligible for immunotherapy (cycles: 4 for ipilimumab and pembrolizumab/ 6 for nivolumab).F-FDG PET/CT imaging was performed prior to (F-FDG PET/CT 0) and 14 weeks after ICI onset (F-FDG PET/CT 1). Some cases during the follow-up required imaging (F-FDG PET/CT 2). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria.Among 37 assessed patients, 27 had 1 line of ICI, 8 had 2 lines of ICI and 2 patients had 3 lines of ICI: total of 49 PET/CTs. Mean time between initiation of ICI and F-FDG PET/CT (1 or 2) were respectively 13.82 ± 4.32 and 24.73 ± 9.53 weeks. Time between F-FDG PET/CT 1 and F-FDG PET/CT 2 was at mean +/- SD: 11.19w ± 5.59. Median PFS was 29.62 months (range 22.52-36.71) (P = .001: RECIST 1.1), (P < .0001: iRECIST), (P = .000: PERCIST), (P = .072: PECRIT). Median OS was 36.62 months (30.46-42.78) (P = .005: RECIST 1.1), (P < .0001: iRECIST), (P = .001: PERCIST), (P = .082 PECRIT).F-FDG PET/CT could detect eventual ICI-response in patients with metastatic melanoma undergoing ICI using iRECIST and PERCIST criteria.
我们旨在根据形态学标准（RECIST1.1、iRECIST）和功能标准（PERCIST、PECRIT）评估连续的F-FDG PET/CT成像，以预测接受免疫检查点阻断剂治疗的晚期黑色素瘤患者的临床反应。对37例符合免疫治疗条件的不可切除转移性皮肤黑色素瘤患者进行回顾性数据收集和分析（疗程：伊匹单抗和帕博利珠单抗为4个周期/纳武单抗为6个周期）。在ICI开始前（F-FDG PET/CT 0）和ICI开始后14周（F-FDG PET/CT 1）进行F-FDG PET/CT成像。随访期间的一些病例需要进行成像（F-FDG PET/CT 2）。根据RECIST1.1、iRECIST、PERCIST和PECRIT标准评估患者的治疗反应。在37例接受评估的患者中，27例接受了1线ICI治疗，8例接受了2线ICI治疗，2例接受了3线ICI治疗：共49次PET/CT检查。ICI开始至F-FDG PET/CT（1或2）的平均时间分别为13.82±4.32周和24.73±9.53周。F-FDG PET/CT 1与F-FDG PET/CT 2之间的时间平均为+/-标准差：11.19周±5.59周。中位无进展生存期为29.62个月（范围22.52-36.71）（P = 0.001：RECIST 1.1），（P < 0.0001：iRECIST），（P = 0.000：PERCIST），（P = 0.072：PECRIT）。中位总生存期为36.62个月（30.46-42.78）（P = 0.005：RECIST 1.1），（P < 0.0001：iRECIST），（P = 0.001：PERCIST），（P = 0.082：PECRIT）。F-FDG PET/CT可以使用iRECIST和PERCIST标准检测接受ICI治疗的转移性黑色素瘤患者的ICI反应情况。
